Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis

Journal of Dermatological Science

Volumn 64, Issue 1, 2011, Pages 1-6

  Miyagaki, Tomomitsu ^a   Sugaya, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Atopic dermatitis; CCR10; Erythrodermic mycosis fungoides; IgE; Prognostic factor; Pruritus; S zary syndrome; Therapy

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE;

ATOPIC DERMATITIS; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RARE DISEASE; REVIEW; SEZARY CELL; SKIN EXAMINATION; SKIN PRURITUS;

ADULT; AGED; DERMATITIS, ATOPIC; DERMATOLOGY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOGLOBULIN E; L-LACTATE DEHYDROGENASE; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MYCOSIS FUNGOIDES; PROGNOSIS; PRURITUS; RECEPTORS, CCR10; RECEPTORS, INTERLEUKIN-2; SEZARY SYNDROME; TREATMENT OUTCOME;

EID: 80052387794     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.07.007     Document Type: Review

References (50)

1. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
2. Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110:1713-1722.
3. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003, 139:857-866.
4. Agar N., Whittaker S.J. Folliculotropic mycosis fungoides (stage IIA) progressing to Sézary syndrome: a case report. Br J Dermatol 2008, 159:1197-1199.
5. Rothe M.J., Bernstein M.L., Grant-Kels J.M. Life-threatening erythroderma: diagnosing and treating the "red man". Clin Dermatol 2005, 23:206-217.
6. Vowels B.R., Cassin M., Vonderheid E.C., Rook A.H. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992, 99:90-94.
7. Dummer R., Geertsen R., Ludwig E., Niederer E., Burg G. Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). Leuk Lymphoma 1998, 28:515-522.
8. Vowels B.R., Lessin S.R., Cassin M., Jaworsky C., Benoit B., Wolfe J.T., et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994, 103:669-673.
9. Asadullah K., Döcke W.D., Haeussler A., Sterry W., Volk H.D. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996, 107:833-837.
10. Meyer N., Paul C., Misery L. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. Acta Derm Venereol 2010, 90:12-17.
11. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109-3115.
12. Papadavid E., Economidou J., Psarra A., Kapsimali V., Mantzana V., Antoniou C., et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2003, 148:709-718.
13. Souwer Y., Szegedi K., Kapsenberg M.L., de Jong E.C. IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol 2010, 22:821-826.
14. Scalabrin D.M., Bavbek S., Perzanowski M.S., Wilson B.B., Platts-Mills T.A., Wheatley L.M. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 1999, 104:1273-1279.
15. Bieber T. The pro- and anti-inflammatory properties of human antigen-presenting cells expressing the high affinity receptor for IgE (Fc epsilon RI). Immunobiology 2007, 212:499-503.
16. Kural Y.B., Su O., Onsun N., Uras A.R. Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T cell lymphoma. Int J Dermatol 2010, 49:390-395.
17. Martí R.M., Estrach T., Reverter J.C., Mascaró J.M. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991, 127:1511-1516.
18. Wasik M.A., Vonderheid E.C., Bigler R.D., Marti R., Lessin S.R., Polansky M., et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996, 132:42-47.
19. Mukai H., Noguchi T., Kamimura K., Nishioka K., Nishiyama S. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol 1990, 17:477-481.
20. Furue M., Sugiyama H., Tsukamoto K., Ohtake N., Tamaki K. Serum soluble IL-2 receptor (sIL-2R) and eosinophil cationic protein (ECP) levels in atopic dermatitis. J Dermatol Sci 1994, 7:89-95.
21. Kakinuma T., Sugaya M., Nakamura K., Kaneko F., Wakugawa M., Matsushima K., et al. Thymus and activation-regulated chemokine (TARC) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003, 48:23-30.
22. Inngjerdingen M., Damaj B., Maghazachi A.A. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. J Immunol 2000, 164:4048-4054.
23. Ferenczi K., Fuhlbrigge R.C., Pinkus J., Pinkus G.S., Kupper T.S. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002, 119:1405-1410.
24. Sokolowska-Wojdylo M., Wenzel J., Gaffal E., Lenz J., Speuser P., Erdmann S., et al. Circulating clonal CLA(+) and CD4(+) T cells in Sézary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005, 152:258-264.
25. Kagami S., Sugaya M., Minatani Y., Ohmatsu H., Kakinuma T., Fujita H., et al. Elevated serum CTACK levels in CTCL. J Invest Dermatol 2006, 126:1189-1191.
26. Miyagaki T., Sugaya M., Fujita H., Ohmatsu H., Kakinuma T., Kadono T., et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 2010, 130:2304-2311.
27. Kakinuma T., Nakamura K., Wakugawa M., Mitsui H., Tada Y., Saeki H., et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001, 107:535-541.
28. Kakinuma T., Saeki H., Tsunemi Y., Fujita H., Asano N., Mitsui H., et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 2003, 111:592-597.
29. Kaburagi Y., Shimada Y., Nagaoka T., Hasegawa M., Takehara K., Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res 2001, 293:350-355.
30. Kagami S., Kakinuma T., Saeki H., Tsunemi Y., Fujita H., Nakamura K., et al. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol 2003, 134:309-313.
31. Harmon C.B., Witzig T.E., Katzmann J.A., Pittelkow M.R. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 1996, 35:404-410.
32. Jones D., Dang N.H., Duvic M., Washington L.T., Huh Y.O. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001, 115:885-892.
33. Wood G.S., Hong S.R., Sasaki D.T., Abel E.A., Hoppe R.T., Warnke R.A., et al. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values. J Am Acad Dermatol 1990, 22:602-607.
34. Scala E., Narducci M.G., Amerio P., Baliva G., Simoni R., Giovannetti A., et al. T cell receptor-Vbeta analysis identifies a dominant CD60+ CD26- CD49d- T cell clone in the peripheral blood of Sézary syndrome patients. J Invest Dermatol 2002, 119:193-196.
35. Scala E., Abeni D., Pomponi D., Narducci M.G., Lombardo G.A., Mari A., et al. The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sézary syndrome. Haematologica 2010, 95:1905-1912.
36. Poszepczynska-Guigné E., Schiavon V., D'Incan M., Echchakir H., Musette P., Ortonne N., et al. CD158k/KIR3DL2 is a new phenotypic marker of Sézary cells: relevance for the diagnosis and follow-up of Sézary syndrome. J Invest Dermatol 2004, 122:820-823.
37. Moretta A., Biassoni R., Bottino C., Pende D., Vitale M., Poggi A., et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997, 155:105-117.
38. Bahler D.W., Hartung L., Hill S., Bowen G.M., Vonderheid E.C. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry. Cytometry B Clin Cytom 2008, 74:156-162.
39. Klemke C.D., Brade J., Weckesser S., Sachse M.M., Booken N., Neumaier M., et al. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers. Br J Dermatol 2008, 159:871-880.
40. Su M.W., Dorocicz I., Dragowska W.H., Ho V., Li G., Voss N., et al. Aberrant expression of T-plastin in Sézary cells. Cancer Res 2003, 63:7122-7127.
41. van Doorn R., Dijkman R., Vermeer M.H., Out-Luiting J.J., van der Raaij-Helmer E.M., Willemze R., et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis. Cancer Res 2004, 64:5578-5586.
42. Soler D., Humphreys T.L., Spinola S.M., Campbell J.J. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 2003, 101:1677-1682.
43. Masui Y., Sugaya M., Kagami S., Fujita H., Yano S., Nagao M., et al. Sézary syndrome treated with narrowband ultraviolet B: time-course measurement of serum levels of CCL17/CCL27. Clin Exp Dermatol 2007, 32:57-59.
44. Olsen E.A., Rook A.H., Zic J., Kim Y., Porcu P., Querfeld C., et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011, 64:352-404.
45. Agar N.S., Wedgeworth E., Crichton S., Mitchell T.J., Cox M., Ferreira S., et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010, 28:4730-4739.
46. Vidulich K.A., Talpur R., Bassett R.L., Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009, 48:243-252.
47. Kim Y.H., Bishop K., Varghese A., Hoppe R.T. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995, 131:1003-1008.
48. Bernengo M.G., Quaglino P., Novelli M., Cappello N., Doveil G.C., Lisa F., et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998, 9:857-863.
49. Foulc P., N'Guyen J.M., Dréno B. Prognostic factors in Sézary syndrome: a study of 28 patients. Br J Dermatol 2003, 149:1152-1158.
50. Marti R.M., Pujol R.M., Servitje O., Palou J., Romagosa V., Bordes R., et al. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2003, 44:59-69.